Skip to content

Clinical trials

Epilepsy trials in the United States with no applicable phase

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Epilepsy Phase: Not applicable Country / region: United States Clear all

219 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20033
20044
20053
20066
20074
20081
20095
20102
20111
20127
201310
20146
20156
201611
201711
201813
201913
20209
202120
202212
202323
202410
202521
202616

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed88
Recruiting49
Enrolling by invitation17
Unknown status17
Withdrawn15
Terminated14
Active, not recruiting12
Not yet recruiting7

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
NYU Langone Health15
Dartmouth-Hitchcock Medical Center14
Mayo Clinic11
University of California, San Francisco7
Wake Forest University Health Sciences6
Brigham and Women's Hospital5
Children's Hospital Medical Center, Cincinnati5
Emory University5
Johns Hopkins University5
Massachusetts General Hospital5

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Epilepsy219
Seizures45
Drug Resistant Epilepsy17
Anxiety Disorders10
Brain Neoplasms5
Cognitive Dysfunction5
Epilepsies, Partial5
Memory Disorders5
Major Depressive Disorder4
Nervous System Diseases4

Trials

Showing 1 to 25 of 219. Each trial links to its page on Pharma Observatory.

119 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.